Omalizumab
Omalizumab is a pharmaceutical drug with 141 clinical trials. Currently 12 active trials ongoing. Historical success rate of 92.9%.
Success Metrics
Based on 104 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
36
Mid Stage
69
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
90.4%
104 of 115 finished
9.6%
11 ended early
12
trials recruiting
141
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Trial of JYB1904 in Patients With Allergic Asthma
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Clinical Trials (141)
Trial of JYB1904 in Patients With Allergic Asthma
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Multi OIT to Test Immune Markers After Minimum Maintenance Dose
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
A Study to Find a Suitable Dose of Exl-111 for Further Research
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Preventing Asthma in High Risk Kids
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
Omalizumab Before Onset of Exacerbations
Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 141